Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib Versus Observation in Early Stage ALK-Positive Non-small Cell Lung Cancer
NCT02201992Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Mar 2015
- Primary completion
- May 2036
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by ECOG-ACRIN Cancer Research Group. Started Mar 2015; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02201992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201992.